Skip to content
10-Q

Quarterly Report

RETINALGENIX TECHNOLOGIES INC. RTGN

0001641172-25-010457

← back to feed
Filed
May 15, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 9, 2025 18.52M sh
Current Liabilities Q1 2025 · Mar 31, 2025 $1.67M
Current Liabilities Q1 2025 · Dec 31, 2024 $1.47M
Total Liabilities Q1 2025 · Mar 31, 2025 $1.68M
Total Liabilities Q1 2025 · Dec 31, 2024 $1.48M
Current Assets Q1 2025 · Mar 31, 2025 $3.71K
Current Assets Q1 2025 · Dec 31, 2024 $6.06K
Total Assets Q1 2025 · Mar 31, 2025 $11.93K
Total Assets Q1 2025 · Dec 31, 2024 $14.95K
Shares Diluted Q1 2025 · Mar 31, 2024 17.67M sh
Operating Cash Flow restated Q1 2025 · Mar 31, 2024 −$163.82K
Stockholders Equity Q1 2025 · Mar 31, 2024 −$1.52M
Stockholders Equity Q1 2025 · Dec 31, 2023 −$1.41M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.12
Eps Basic Q1 2025 · Mar 31, 2024 −$0.12
Sga Expense Q1 2025 · Mar 31, 2024 $328.99K
Rd Expense Q1 2025 · Mar 31, 2024 $83.1K
Net Income Q1 2025 · Mar 31, 2024 −$2.15M